IP Library Granted Patent US 9,458,238
Granted Patent B2
US 9,458,238 · App. 14/515,892 · Granted Oct 4, 2016

Nucleic acid molecules encoding antibodies which bind CCR4 and uses thereof

Inventors: Urs Beat Hagemann (Oslo, NO); Remko Albert Griep (Slemmestad, NO); Herald Reiersen (Sofiemyr, NO); Sergej Michailovi{hacek over (c)} Kiprijanov (Oslo, NO)
Assignee: Cancer Research Technology Limited
C07K16/2866A61K2039/505C07K2317/14C07K2317/21C07K2317/33C07K2317/41C07K2317/565C07K2317/622C07K2317/732C07K2317/76G01N2333/7158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,458,238
App. No.
14/515,892
Granted
Oct 4, 2016
Kind
B2
Abstract

The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Claims (27)

1. A nucleic acid molecule comprising a nucleotide sequence encoding an antibody which binds to human CC chemokine receptor 4 (CCR4) and which is capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4, and which comprises at least one heavy chain variable region that comprises three CDRs and at least one light chain variable region that comprises three CDRs,

wherein said heavy chain variable region comprises

(i) a variable heavy (VH) CDR1 that has the amino acid sequence of SEQ ID NO: 1,

(ii) a variable heavy (VH) CDR2 that has the amino acid sequence of SEQ ID NO: 2, and

(iii) a variable heavy (VH) CDR3 that has the amino acid sequence of SEQ ID NO: 20;

and wherein said light chain variable region of said antibody comprises:

(iv) a variable light (VL) CDR1 that has the amino acid sequence of SEQ ID NO: 22;

(v) a VL CDR2 that has the amino acid sequence of SEQ ID NO: 5; and

(vi) a VL CDR3 that has the amino acid sequence of SEQ ID NO: 24.

2. A nucleic acid molecule comprising a nucleotide sequence encoding an antibody which binds to human CC chemokine receptor 4 (CCR4) and which is capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4, wherein said antibody

has a VH domain having the sequence of SEQ ID NO: 39 and/or a VL domain having the sequence of SEQ ID NO: 40.

3. The nucleic acid molecule of claim 1 , wherein said nucleotide sequence has SEQ ID NO: 111 and/or 112.

4. An expression vector comprising the nucleic acid molecule of claim 1 .

5. An expression vector comprising the nucleic acid molecule of claim 2 .

6. An expression vector comprising the nucleic acid molecule of claim 3 .

7. A host cell or virus comprising the nucleic acid molecule of claim 1 .

8. A host cell or virus comprising the nucleic acid molecule of claim 2 .

9. A host cell or virus comprising the nucleic acid molecule of claim 3 .

10. A method of producing an antibody, comprising:

(a) culturing a host cell that comprises an expression vector comprising the nucleic acid molecule of claim 1 under conditions effective to express the encoded antibody; and

(b) obtaining the expressed antibody from said host cell.

11. A method of producing an antibody, comprising:

(c) culturing a host cell that comprises an expression vector comprising the nucleic acid molecule of claim 2 under conditions effective to express the encoded antibody; and

(d) obtaining the expressed antibody from said host cell.

12. A method of producing an antibody, comprising:

(e) culturing a host cell that comprises an expression vector comprising the nucleic acid molecule of claim 3 under conditions effective to express the encoded antibody; and

(f) obtaining the expressed antibody from said host cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2016
From: AFFITECH A/S
To: CANCER RESEARCH TECHNOLOGY LIMITED
Reel/Frame 039485/0010 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2016
From: AFFITECH RESEARCH AS
To: AFFITECH A/S
Reel/Frame 039478/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2016
From: HAGEMANN, URS BEAT; GRIEP, REMKO ALBERT; REIERSEN, HERALD; KIPRIJANOV, SERGEJ MICHAILOVIC
To: AFFITECH RESEARCH AS
Reel/Frame 039715/0539 →
Continuity (3)
Division 13313541 · Dec 7, 2011
Provisional Application 61420370 · Dec 7, 2010
Related Publication 20150104831A1 · Apr 16, 2015